Research programme: allogenic CAR-T therapeutics - Celyad Oncology
Alternative Names: CYAD-200 series; CYAD-221; CYAD-231Latest Information Update: 28 Apr 2023
At a glance
- Originator Celyad
- Developer Celyad Oncology; Horizon Discovery
- Class Antineoplastics; CAR-T cell therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported B-cell lymphoma; Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in B-cell lymphoma in Belgium (Parenteral)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in Belgium (Parenteral)
- 10 Jun 2020 Celyad is now called Celyad Oncology